. Author manuscript; available in PMC: 2018 May 11.

Published in final edited form as: Biotechnol Bioeng. 2017 Jun 29;114(10):2379–2389. doi: 10.1002/bit.26345

Table I.

Left Ventricular Function and Geometry Four Weeks Post-MI

	PBS	HGFdf	SHIELD	SHIELD+HGFdf	Sham

FAC, %	17.7±1.6	20.0±2.5	20.8±0.7	27.7±1.1	51.2±3.6
FAC, %	p=0.0012	p=0.039	p=0.089	27.7±1.1	p<0.001

EF, %	27.4+1.6	29.0±2.9	32.1±1.0	40.0±0.9	69.5±3.9
EF, %	p=0.00013	p=0.0022	p=0.046	40.0±0.9	p<0.001

SV, μL	216.1±15.5	197.5±21.7	241.3±13.1	318.3±13.7	365.6±28.4
SV, μL	p=0.00051	p=0.00012	p=0.022	318.3±13.7	p=1.0

Vs, μL	628.9±128.7	547.9±96.3	571.4±128.0	459.2±90.7	195.0±26.0
Vs, μL	p=0.0084	p=0.91	p=0.33	459.2±90.7	p<0.001

LVIDs	8.1±0.3	8.0±0.3	8.3±0.3	7.0±0.2	4.0±0.3
LVIDs	p=0.053	p=0.16	p=0.034	7.0±0.2	p<0.001

LVIDd	9.0±0.2	9.3±0.2	9.6±0.4	8.6±0.2	7.4±0.3
LVIDd	p=0.71	p=0.14	p=0.16	8.6±0.2	p<0.001

P values refer to comparison between SHIELD+HGFdf group and the control group, PBS, SHIELD alone or HGFdf alone. Values reported at mean±standard error of the mean. EF indicates ejection fraction; FAC, fractional area change; HGFdf, engineered hepatocyte growth factor dimeric fragment; LVIDd, left ventricular inner diameter at end diastole; LVIDs, left ventricular inner diameter at end systole; PBS, phosphate buffered saline; SHIELD, shear-thinning hydrogel for injection encapsulation and long-term delivery; SV, stroke volume; and Vs, volume at end systole.